Lysophosphatidic acid-1-receptor targeting agents for fibrosis
The DOI matches its Crossref record; 9 of the 9 references it cites were found in a registry or an index.
Abstract
INTRODUCTION: The presence of fibrosis is associated with alterations in organ architecture and is responsible for the morbidity of diseases including pneumopathies, systemic sclerosis, liver cirrhosis, chronic cardiovascular diseases, progressive kidney diseases and diabetes. Although a growing number of pro-fibrotic molecules, mediators and other pathways have been reported, there are currently very few antifibrotic molecules being evaluated in clinical trials. AREAS COVERED: Current knowledge about the contribution of lysophosphatidic acid (LPA), a bioactive mediator acting via specific G-protein coupled receptors (LPAR), in the etiology of fibrosis. In a number of organs, fibrosis is associated with increased LPA production as well as with increased expression of some LPAR subtypes (mainly LPA1R). LPAR(-/-) knockout mice and treatment of animal models with specific antagonists clearly demonstrate the contribution of LPA1R subtype to the development of kidney, lung, vascular and dermal fibrosis. The involvement of LPA in liver fibrosis is also strongly suspected but still unproven. EXPERT OPINION: Experiments in animal models clearly demonstrate that LPA1R antagonists have interesting anti-fibrotic potencies. This reveals promising perspectives for the design of new therapeutic approaches to prevent fibrosis-associated diseases. Nevertheless, the number of efficient LPA1R antagonists currently available is still low, and none of them has been used in clinical trials so far.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Cellular and molecular mechanisms of fibrosis
Wynn, T. (2008) · The Journal of Pathology · doi:10.1002/path.2277 · Cited by 4,495
Matrix Crosslinking Forces Tumor Progression by Enhancing Integrin Signaling
Levental, K. R., Yu, H., Kass, L., Lakins, J. N., Egeblad, M., Erler, J. T., Fong, S. F. T., Csiszar, K., Giaccia, A., Weninger, W., et al. (2009) · Cell · doi:10.1016/j.cell.2009.10.027 · Cited by 4,101
Pathogenesis of Liver Fibrosis
Hernandez-Gea, V., & Friedman, S. L. (2011) · Annual Review of Pathology: Mechanisms of Disease · doi:10.1146/annurev-pathol-011110-130246 · Cited by 1,809
Tager, A. M., LaCamera, P., Shea, B. S., Campanella, G. S., Selman, M., Zhao, Z., Polosukhin, V., Wain, J., Karimi-Shah, B. A., Kim, N. D., et al. (2008) · Nature Medicine · doi:10.1038/nm1685 · Cited by 823 · cited 2×
“Furthermore, bronchoalveolar lavage fluid obtained from idiopathic pulmonary fibrosis patients induced chemotaxis of human foetal lung fibroblasts that was blocked by the LPA1R antagonist Ki16425 [59].”
BackgroundHenegar, C., Tordjman, J., Achard, V., Lacasa, D., Cremer, I., Guerre-Millo, M., Poitou, C., Basdevant, A., Stich, V., Viguerie, N., et al. (2008) · Genome Biology · doi:10.1186/gb-2008-9-1-r14 · Cited by 471 · cited 1×
“In such affection, fibrosis affects several organs including kidney, liver, heart or the adipose tissue, and its intensity is negatively correlated with the degree of insulin-sensitivity [108-112].”
BackgroundChua, F., Gauldie, J., & Laurent, G. J. (2005) · American Journal of Respiratory Cell and Molecular Biology · doi:10.1165/rcmb.2005-0062tr · Cited by 305
Sahai, A., Malladi, P., Pan, X., Paul, R., Melin-Aldana, H., Green, R. M., & Whitington, P. F. (2004) · American Journal of Physiology-Gastrointestinal and Liver Physiology · doi:10.1152/ajpgi.00199.2004 · Cited by 290 · cited 1×
“In such affection, fibrosis affects several organs including kidney, liver, heart or the adipose tissue, and its intensity is negatively correlated with the degree of insulin-sensitivity [108-112].”
BackgroundMechanistic basis of Rho GTPase-induced extracellular matrix synthesis in trabecular meshwork cells
Pattabiraman, P. P., & Rao, P. V. (2010) · American Journal of Physiology-Cell Physiology · doi:10.1152/ajpcell.00317.2009 · Cited by 189
Wiedmaier, N., Müller, S., Köberle, M., Manncke, B., Krejci, J., Autenrieth, I. B., & Bohn, E. (2008) · International Journal of Medical Microbiology · doi:10.1016/j.ijmm.2007.06.001 · Cited by 34
Cited by
Molecular and cellular mechanisms of liver fibrosis and its regression
Kisseleva, T., & Brenner, D. (2021) · Nature Reviews Gastroenterology & Hepatology · doi:10.1038/s41575-020-00372-7 · Cited by 2,024
Cytosolic phospholipase A2: physiological function and role in disease
Leslie, C. C. (2015) · Journal of Lipid Research · doi:10.1194/jlr.r057588 · Cited by 413
Understanding fibrosis in systemic sclerosis: shifting paradigms, emerging opportunities
Bhattacharyya, S., Wei, J., & Varga, J. (2012) · Nature Reviews Rheumatology · doi:10.1038/nrrheum.2011.149 · Cited by 381
The role of myofibroblasts in wound healing
Hinz, B. (2016) · Current Research in Translational Medicine · doi:10.1016/j.retram.2016.09.003 · Cited by 328
Varga, J., Trojanowska, M., & Kuwana, M. (2017) · Journal of Scleroderma and Related Disorders · doi:10.5301/jsrd.5000249 · Cited by 323
Metadata
- Authors
- Rancoule, C., Pradère, J.-P., Gonzalez, J., Klein, J., Valet, P., Bascands, J.-L., Schanstra, J. P., & Saulnier-Blache, J.-S.
- Venue
- Expert Opinion on Investigational Drugs
- Publisher
- Informa UK Limited
- Published
- 2011-03-24
- Volume
- 20
- Issue
- 5
- Pages
- 657-667
- ISSN
- 1354-3784 (ISSN-L)
- 1744-7658
- OpenAlex
- W2040769700
- Cited by
- 84
- References
- 9
- FWCI
- 3.06
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Lysophosphatidic acid-1-receptor targeting agents for fibrosis. https://app.cochat.ai/papers/10.1517/13543784.2011.566864
- The paper
- Rancoule, C., Pradère, J.-P., Gonzalez, J., Klein, J., Valet, P., Bascands, J.-L., Schanstra, J. P., & Saulnier-Blache, J.-S. (2011). Lysophosphatidic acid-1-receptor targeting agents for fibrosis. Expert Opinion on Investigational Drugs. https://doi.org/10.1517/13543784.2011.566864
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.